831P - Impact of chronic kidney disease on disease outcomes in hospitalized multiple myeloma patients: A National inpatient sample study from 2016 to 2020

Background

Further studies are needed on outcomes of hospitalizations in patients with multiple myeloma (MM) and chronic kidney disease (CKD). The objective of our study was to use the National Inpatient Sample (NIS) to determine inpatient outcomes for patients with MM with and without CKD.

Methods

This is a retrospective study using the NIS data from 2016 to 2020. Patients aged 18 years or older who were admitted with a primary diagnosis of MM were included. The cohort was then categorized into patients with MM and concomitant CKD vs those with MM and without CKD. Baseline characteristics were compared between both groups. The study primary outcome was inpatient mortality. Multivariate logistic regression analysis was performed to analyze predictors and risks of mortality.

Results

A total of 97,995 admissions with the diagnosis of MM were identified. Of those, 19.7% had a concomitant diagnosis of CKD, and 80.3% did not have CKD. The baseline characteristics of both cohorts are described in the table. Patients with CKD were more likely to have Heart Failure (HF) (23.1% vs 8.9%, p<0.001) than those without CKD. In total, 4755 patients died during their hospitalization, which accounts for 4.85% of the total. Among those, mortality for patients with CKD was 7.86% vs 4.12% in those without CKD. Additionally, CKD was not significantly associated with increased mortality risk. However, HF was associated with an increased risk of mortality (OR 2.05, CI 1.72-2.44, p<0.001) in patients with MM. Asian or Pacific Islander race and races listed as other had a higher mortality risk than white race (OR 1.66, p=0.005, and OR 1.61, p=0.002, respectively). Urban teaching hospitals had a decreased mortality compared to rural hospitals (OR 0.59, CI 0.43-0.82, p=0.001).

Conclusions

Our data analysis demonstrated that mortality did not increase in hospitalized patients with MM and CKD vs those without CKD over a 5-year period. We concluded that CKD by itself does not affect mortality in MM patients, but other comorbidities such as HF and location of hospital do affect mortality outcomes in hospitalized MM patients. Further research is necessary to address these findings.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.